ANTIHYPERLIPIDEMIC USE AMONG ADULTS AGED 40 YEARS AND MORE WITH TYPE 2 DIABETES- ASSESSMENT OF RACIAL DISPARITIES

Author(s)

Parmar S1, Hijazi B1, Makawi A1, Levin A1, Perez A2
1Nova Southeastern University, Davie, FL, USA, 2Nova Southeastern University College of Pharmacy, Davie, FL, USA

Presentation Documents

OBJECTIVE: To evaluate antihyperlipidemic agent use among non-Hispanic white, black, and Hispanic and Asian adults with type 2 diabetes in the United States who quality for primary or secondary prevention of cardiovascular disease.METHODS: This is a retrospective cohort study that uses the cross-sectional National Health and Nutrition Examination Survey cohorts 2011-2016. Adults 40 year of age or older with type 2 diabetes self-described as non-Hispanic white, black, and Hispanic and Asian were included in this study. This is a population who is at higher risk of cardiovascular disease. Study outcome was defined as use of any antihyperlipidemic agent approved in the United States and was compared across racial/ethnic groups. All racial/ethnic minority groups including Hispanic and Asians have been over-sampled in this survey and all analyses have been adjusted for complex sample design. Socio-demographic parameters and additional cardiovascular risk factors were also collected and compared across racial/ethnic groups. Chi-squared and 1-way ANOVA were used to compare categorical (outcome and predictors) and continuous (predictors) across racial/ethnic groups. All estimates are nationally representative. An alpha of 5% was used. RESULT: 1830 participants were included and represent 18 million individuals nationally. The overall use of antihyperlipidemic agents was 41%. Differences in antihyperlipidemic agent use were observed across racial/ethnic groups: white (49.8%), black (38.6%), Hispanic (34.6%) and Asian (44.7%) and were statistically significant (p<0.05). Statistical differences of cardiovascular risk factors were observed across study groups and Asians we found to have more favorable risk factor trends than other study groups. CONCLUSION: This is the first national study to report antihyperlipidemic agent use in Asians and to evaluate their cardiovascular risk compared to other racial/ethnic groups. Overall, use of agents was low in a population that continues to have a high risk of cardiovascular disease.

Conference/Value in Health Info

2020-05, ISPOR 2020, Orlando, FL, USA

Code

PDB91

Disease

Cardiovascular Disorders, Diabetes/Endocrine/Metabolic Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×